MK-1084 is an orally bioavailable and low-dose KRAS/G12C covalent inhibitor with IC50 of 1.2 nM (GNE) and 9 nM (p-ERK), respectively.

KM822 is avselective, noncompetitive modulator of human dopamine transporter (DAT) with IC50 3.7 μM, which shows 30 and 50 folds higher than for human norepinephrine transporter (hNET) and human serotonin transporter (SERT), respectively.

CNDR-51997 is a brain-penetrant microtubule alterations-stabilizing small molecule and reduces both Aβ plaque and tau inclusion pathology in established mouse models of Alzheimer's disease.

OPB-171775 is a non-TKI compound that exhibits significant anticancer activity against gastrointestinal stromal tumor (GIST) regardless of KIT mutation status. OPB-171775 induces targeted cell death by inducing a complex between phosphodiesterase 3A (PDE3A) and Schlafen family member 12 (SLFN12).

NF764 is an analogue of EN83 (CTNNB1 degrader) with improved potency with DC50 of 3.5 nM. NF764 only adducts C619 and shows much more selective than EN83 with 61 significant off-targets.

EN83 is a monovalent degrader of CTNNB1 that directly and covalently targets CTNNB1 three cysteines C466, C520, and C619, leading to destabilization and degradation of CTNNB1.

DHSEH is a sulfonium lipid for lung-specific mRNA delivery.

DOSEH is a sulfonium lipid for lung-specific mRNA delivery.

Bivamelagon is a melanocortin receptor agonist.

Turbinaric acid is a moderately cytotoxic secosqualene carboxylic acid that is isolated from the brown alga Turbinaria ornata.

IDH1 Inhibitor 8 (91) is isocitrate dehydrogenase 1 (IDH1) inhibitor. IDH1 Inhibitor 8 can be used for the research of cancer.

SDPC (DHA-PC) is a new generation of omega-3 lipids, which contains an ester bond linking DHA at the sn-2 position of phospholipid. 1-Stearoyl-2-docosahexaenoyl-sn-glyerco-3-phosphocholine exerts anti-angiogenesis effect through activating PPARγ. 1-Stearoyl-2-docosahexaenoyl-sn-glyerco-3-phosphocholine significantly declines the proliferation, migration, tube formation of human umbilical vein endothelial cells. 1-Stearoyl-2-docosahexaenoyl-sn-glyerco-3-phosphocholine has the potential for anti-tumor angiogenesis research.

T-10418 is a potent and selective G2A agonist with EC50 of 0.82 μM. T-10418 exhibits higher potency than the reference and natural ligand 9-HODE and high selectivity among G protein-coupled receptors. T-10418 is a suitable candidate for in vivo studies on therapeutic potential of G2A agonism.

TG6A is a biodegradable and ionizable glycerolipid for cmRNA delivery. TG6A-LNP exhibits above 9-fold and 41-fold higher EGFP protein expression in MSCs than DLin-MC3-DMA-LNP and ALC-0315-LNP, respectively.

AZ'9567 is a potent inhibitor of MAT2A with pIC50 of 8.2. in vitro with excellent preclinical pharmacokinetic properties. AZ'9567 shows robust antitumor response in the MTAP KO HCT116 model.

LL-K12-18 is a dual-site molecular glue for CDK12-DDB1 complex with EC50 of 0.37 nM. LL-K12-18 shows an 80-fold enhanced potency than SR-4835 in MDA-MB-231 cells and with a 307-fold boost potency (EC50 = 0.03 nM) in MDA-MB-468 cells, while the degradation efficiency (DC50 = 0.38 nM) increased 50-fold.

DS18 is a DDB1-CDK12 molecular glue with EC50 of 8.771 nM.

Lipid A1-D1-5 is an ionizable lipid-like substance used for RNA interference therapy in heat-stable ionizable lipid-like nanoparticles (iLAND) for the treatment of hyperlipidemia.